Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 8/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.36 |
| ▸ | SGK1 | O00141 | 1/20 | 0.35 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 2/20 | 0.34 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3108955 | 0.82 | NR1H4 (0.53) | MYCATMNR1H4EPHX2S1PR1 | |
| SCHEMBL3117970 | 0.78 | S1PR1 (0.35) | MYCNR1H4EPHX2S1PR1VSIR | |
| SCHEMBL3105107 | 0.75 | ADRB3 (0.41) | ADRB3ADRB1ADRB2SGK1CAMKK2 | |
| SCHEMBL5038405 | 0.75 | MEP1B (0.60) | MYCNR1H4 | |
| SCHEMBL5780166 | 0.75 | HIF1A (0.43) | ATMPTPRCVSIR | |
| SCHEMBL1243790 | 0.74 | ALDH1A1 (0.51) | ATMNR1H4EPHX2 | |
| SCHEMBL27904830 | 0.74 | GABRA1 (0.56) | ADRB3ADRB1ADRB2SGK1CAMKK2 | |
| SCHEMBL27888038 | 0.74 | GABRA1 (0.56) | ADRB3ADRB1ADRB2SGK1CAMKK2 | |
| SCHEMBL734928 | 0.72 | ATM (0.55) | ATMPTPRC | |
| SCHEMBL24845984 | 0.72 | SLC7A5 (0.50) | ATMPTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179109-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179109-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | ADRB3 729/4885ADRB1 395/4885MYC 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.